Every Form 4 that Revolution Medicines, Inc. (RVMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RVMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVMD filings page.
Revolution Medicines (RVMD) President and CEO Mark A. Goldsmith reported an option exercise and stock sale. On 11/18/2025, he exercised a stock option for 20,000 shares of common stock at an exercise price of $4.09 per share, then sold 20,000 shares of common stock in open market transactions at a weighted average price of $70.3793 per share.
After these transactions, he directly beneficially owned 247,863 shares of common stock, which includes 193,475 restricted stock unitsRule 10b5-1 trading plan adopted on December 19, 2024, indicating the trades were pre-arranged under that plan.
Revolution Medicines, Inc. (RVMD) reported an insider equity transaction by its General Counsel, who is an officer of the company. On 11/18/2025, the officer exercised a stock option for 13,388 shares of common stock at an exercise price of $42.45 per share, then sold 13,388 shares of common stock on the same date at a weighted average price of $70.138 per share. After these transactions, the officer beneficially owned 50,425 shares of common stock, which includes 43,910 restricted stock units. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025.
Revolution Medicines (RVMD) reported an insider transaction on a Form 4. CFO Jack Anders exercised 10,000 stock options at $17 and sold 10,000 common shares at $64 on November 11, 2025 pursuant to a Rule 10b5-1 plan adopted on December 16, 2024.
After these transactions, Anders beneficially owned 110,994 shares, which include 48,275 restricted stock units. The option exercised related to an award with a $17 exercise price (exercisable from 02/12/2024 to 02/11/2030), with 5,418 derivative securities remaining beneficially owned.
Revolution Medicines (RVMD) — Form 4 insider activity: President and CEO Mark A. Goldsmith reported option exercises and share sales on 11/07/2025 pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024. He exercised options for 26,479 shares at $1.12 and 3,521 shares at $4.09, then sold 30,000 shares at a weighted average price of $60.3102 (trades ranged from $60.00 to $60.88).
On 11/12/2025, he recorded transfers of 50,000 shares to the Jonathan Goldsmith Revocable Trust and 50,000 shares to the Rebecca Goldsmith Revocable Trust, and reported indirect holdings in multiple family trusts. Following the transactions, direct beneficial ownership amounts were updated across entries, and his beneficial holdings include 193,475 restricted stock units.
Revolution Medicines (RVMD) reported insider activity by General Counsel Jeff Cislini. On October 17, 2025, he exercised 12,000 stock options at $36.57 and sold 12,000 shares at $55 pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.
After these transactions, he beneficially owned 50,425 shares, including 43,910 restricted stock units. The exercised option carried a $36.57 exercise price, became exercisable on June 15, 2024, and expires on June 16, 2030. Following the activity, 18,000 derivative securities remained beneficially owned.
Revolution Medicines (RVMD) insider activity: On October 16–17, 2025, President & CEO and director Mark A. Goldsmith exercised 20,000 stock options at $1.12 and sold 20,000 common shares pursuant to a Rule 10b5-1(c) trading plan adopted on December 19, 2024. Sales were 10,000 shares at a weighted average $50.4701 on Oct 16 and 10,000 shares at $55 on Oct 17.
Following these transactions, he directly beneficially owns 452,309 shares, which includes 193,475 restricted stock units. He also reports indirect holdings of 20,424, 20,424, and 465,604 shares held in family trusts. After the option exercises, 26,479 stock options remain beneficially owned.
Revolution Medicines (RVMD) reported an insider transaction by an officer on 10/13/2025. The reporting person exercised 25,000 stock options at an exercise price of $4.73 per share, then sold 25,000 shares of common stock at a weighted average price of $48.5416. The trades were made under a Rule 10b5-1 trading plan adopted on February 28, 2025.
Following these transactions, the reporting person beneficially owned 284,047 shares, which includes 84,000 restricted stock units, held directly. The filing also shows 5,055 derivative securities (stock options) remaining beneficially owned. The officer’s title is President, Research and Development.
Jeff Cislini, General Counsel of Revolution Medicines, Inc. (RVMD), reported an insider sale. On 09/24/2025 he disposed of 1,799 shares of common stock at a price of $44.26 per share under a previously adopted 10b5-1 trading plan. After the sale he beneficially owned 50,425 shares in total, which the filing specifies includes 43,910 restricted stock units. The Form 4 was signed on behalf of Mr. Cislini by an attorney-in-fact on 09/26/2025.
Wei Lin, Chief Medical Officer of Revolution Medicines, Inc. (ticker shown in filing as RVMD), reported a sale of 2,160 shares of Common Stock on 09/16/2025 at a price of $45.8249 per share. The filing states the sale was made under a Rule 10b5-1 instruction adopted on December 23, 2024 to satisfy the reporting person’s tax withholding obligation upon the vesting of restricted stock units (RSUs) after March 15, 2025. After the transaction, Wei Lin beneficially owned 88,339 shares, which the filing notes includes 58,850 restricted stock units. The form was signed by an attorney-in-fact on behalf of Wei Lin on 09/18/2025.
Revolution Medicines insider sale to cover RSU taxes — The company's President of Research and Development, Stephen Michael Kelsey, reported a sale of 5,367 shares of common stock at $45.8249 per share executed under a Rule 10b5-1 plan to satisfy tax withholding on restricted stock unit vesting. After the transaction the filing reports beneficial ownership of 284,047 shares, which includes 84,000 RSUs. The sale is described as pursuant to a pre-existing 10b5-1 instruction adopted in May 2023.
Margaret A. Horn, Chief Operating Officer and Director of Revolution Medicines, reported a sale of 4,775 shares of the issuer's common stock on 09/16/2025 at a reported price of $45.8249 per share. After the transaction she beneficially owns 145,900 shares, which the filing states includes 70,500 restricted stock units (RSUs). The sale was executed under a Rule 10b5-1 instruction letter adopted May 31, 2023, to satisfy the reporting person's tax withholding obligations upon RSU vesting after July 15, 2023. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Horn on 09/18/2025.
Insider sale to cover taxes: This Form 4 shows Jeff Cislini, General Counsel of Revolution Medicines, executed a sale of 1,869 shares of common stock on 09/16/2025 at $45.8249 per share under a Rule 10b5-1 plan adopted May 31, 2023 to satisfy tax withholding for vested restricted stock units (RSUs). After the transaction he beneficially owns 52,224 shares, which includes 43,910 RSUs. The filing was signed by an attorney-in-fact on 09/18/2025. The disclosure is a routine insider tax-withholding sale rather than a discretionary trade.
Revolution Medicines insider sale to cover tax withholding following RSU vesting. Chief Financial Officer Jack Anders reported a sale of 2,320 shares of Revolution Medicines common stock on 09/16/2025 at an average price of $45.8249 per share, executed under a pre-existing Rule 10b5-1 instruction adopted May 31, 2023 to satisfy tax withholding obligations tied to RSU vesting after July 15, 2023. After the transaction Mr. Anders beneficially owned 110,994 shares, which the filing notes includes 48,275 restricted stock units. The Form 4 is signed and dated 09/18/2025.